Education
About Us
Working with TipRanks
Follow Us
Pds Biotechnology (PDSB)
:PDSB
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.3Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 12.90%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements, including the initiation of a pivotal Phase 3 trial and promising Phase 2 results, as well as successful fundraising efforts. However, challenges such as increased net interest expenses and the need for further capital to complete the trial were noted, indicating a balanced outlook.Company Guidance
During the PDS Biotech Fourth Quarter and Full Year 2024 Earnings Conference Call, the management team provided insights into their clinical and financial progress. They highlighted the initiation of the VERSATILE-003 Phase 3 clinical trial for HPV16-positive head and neck cancer, with a design including 350 patients and a 2:1 randomization. The trial aims to improve upon the median overall survival of 17.9 months seen with pembrolizumab alone, with past data showing a median overall survival of 30 months for their combination therapy. Key metrics from the VERSATILE-002 Phase 2 trial show improvements such as a 36% objective response rate, a 77% disease control rate, and a 21% complete or near-complete response rate. Financially, the company reported a net loss of $37.6 million for 2024, down from $42.9 million in 2023, primarily due to decreased operating expenses. The company also raised $11 million in a direct offering and plans further funding to support the VERSATILE-003 trial.Initiation of VERSATILE-003 Phase 3 Clinical Trial
PDS Biotech initiated the VERSATILE-003 Phase 3 clinical trial for first line recurrent and/or metastatic HPV16-positive head and neck squamous cell carcinoma. The trial involves approximately 350 patients and aims to demonstrate the efficacy of Versamune HPV + pembrolizumab.
Promising Results from VERSATILE-002 Phase 2 Study
The VERSATILE-002 Phase 2 study showed a median overall survival of 30 months, an objective response rate improvement from 26% to 36%, and a disease control rate improvement from 70% to 77%.
FDA Clearance for MUC1 IND Application
FDA cleared the IND application for the combination of Versamune MUC1 and PDS01ADC to treat metastatic colorectal cancer, representing a significant development for PDS Biotech.
Decreased Net Loss for 2024
Net loss for 2024 was $37.6 million, down from $42.9 million in 2023, primarily due to decreased operating expenses.
Successful Fundraising
PDS Biotech completed an up to $22 million registered direct offering, with $11 million upfront and potential for an additional $11 million from warrant exercises.
---
PDSB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PDSB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.24 | $1.25 | +0.81% |
| Nov 14, 2024 | $2.76 | $2.25 | -18.48% |
| Aug 13, 2024 | $3.05 | $3.05 | 0.00% |
| May 15, 2024 | $3.54 | $3.50 | -1.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pds Biotechnology (PDSB) report earnings?
Pds Biotechnology (PDSB) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is Pds Biotechnology (PDSB) earnings time?
Pds Biotechnology (PDSB) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PDSB EPS forecast?
PDSB EPS forecast for the fiscal quarter 2025 (Q1) is -0.25.
---